Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Dependency of Survival on Additional Karyotype Anomalies and Bone Marrow Blast Count in Patients Suffering from Myelodysplastic Syndromes with 5q Deletion.

Sabine Knipp, Barbara Hildebrandt, Martine Jotterand, Marc Schapira, Aristoteles Giagounidis, Norbert Gattermann, Carlo Aul, Ulrich Germing

Blood (2007) 110 (11): 2459.

https://doi.org/10.1182/blood.V110.11.2459.2459

Published: 2007

Journal Articles

Defibrotide Effectively Prevents Veno-Occlusive Disease of the Liver (VOD) after Allogeneic Stem Cell Transplantation. An Extended Study.

Yves Chalandon, MD, Eddy Roosnek, PhD, Claudine Helg, MD, Frank Verholen, MD, Sabine Knipp, MD, Hulya Ozsahin, MD, Jakob R. Passweg, MD, MS

Blood (2006) 108 (11): 2962.

https://doi.org/10.1182/blood.V108.11.2962.2962

Published: 2006

Journal Articles

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.

Michael Lübbert, Björn Rüter, Mathias Schmid, Sabine Knipp, Ulrich Germing, Christiane Dobbelstein, Hartmut Eimermacher, Barbara Deschler, Rainer Claus, Richard Schlenk, Arnold Ganser, Hartmut Döhner, Claudia Schmoor, Hartmut Henß

Blood (2005) 106 (11): 1852.

https://doi.org/10.1182/blood.V106.11.1852.1852

Published: 2005

Journal Articles

Induction of Complete Remission with 5-Azacytidine in a Patient with Acute Myeloid Leukemia Refractory to Intensive Chemotherapy.

Andrea Kuendgen, MD, Thorsten Graef, MD, Sabine Knipp, MD, Barbara Hildebrandt, MD, Akos Czibere, MD, Ali N. Huenerlituerkoglu, MD, Ulrich Germing, MD, Rainer Haas, MD, Norbert Gattermann, MD, Guido Kobbe, MD

Blood (2005) 106 (11): 4600.

https://doi.org/10.1182/blood.V106.11.4600.4600

Published: 2005

Journal Articles

Exisulind Selectively Induces Apoptosis Via C-Jun Kinase Activation in MDS and sAML/MDS.

Akos Czibere, MD, Wolf C. Prall, MD, Sabine Knipp, MD, Andrea Kuendgen, MD, Luiz F. Zerbini, PhD, Ulrich Germing, MD, Rainer Haas, MD, Towia A. Libermann, PhD, Norbert Gattermann, MD, Manuel Aivado, MD

Blood (2005) 106 (11): 4902.

https://doi.org/10.1182/blood.V106.11.4902.4902

Published: 2005

Journal Articles

A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.

Luca Malcovati, MD, Ulrich Germing, MD, Andrea Kuendgen, MD, Matteo G. Della Porta, MD, Rosangela Invernizzi, MD, Aristoteles Giagounidis, MD, Barbara Hildebrandt, PhD, Paolo Bernasconi, MD, Sabine Knipp, MD, Mario Lazzarino, MD, Corinna Strupp, MD, Mario Cazzola, MD

Blood (2005) 106 (11): 788.

https://doi.org/10.1182/blood.V106.11.788.788

Published: 2005

Journal Articles

Valproic Acid (VPA) Achieves High Response Rates in Patients with Low-Risk Myelodysplastic Syndromes.

Andrea Kuendgen, MD, Mathias Schmid, MD, Sabine Knipp, MD, Akos Czibere, MD, Barbara Hildebrandt, MD, Christian Steidl, MD, Rainer Haas, MD, Ulrich Germing, MD, Hartmut Doehner, MD, Norbert Gattermann, MD

Blood (2005) 106 (11): 789.

https://doi.org/10.1182/blood.V106.11.789.789

Published: 2005

Journal Articles

Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes

Akira Matsuda, Ulrich Germing, Itsuro Jinnai, Motohiro Misumi, Andrea Kuendgen, Sabine Knipp, Manuel Aivado, Masako Iwanaga, Yasushi Miyazaki, Hideki Tsushima, Mari Sakai, Masami Bessho, Masao Tomonaga

Blood (2005) 106 (8): 2633–2640.

https://doi.org/10.1182/blood-2005-01-0040

Published: 2005

Journal Articles

Intensive Chemotherapy Is Not Recommended for Patients with AML or High-Risk MDS Aged over 60 Years with Complex Karyotype Anomalies.

Sabine Knipp, MD, Barbara Hildebrandt, PhD, Aristoteles A.N. Giagounidis, MD, Guido Kobbe, MD, Rainer Haas, MD, Carlo Aul, MD, Norbert Gattermann, MD, Ulrich Germing, MD

Blood (2004) 104 (11): 72.

https://doi.org/10.1182/blood.V104.11.72.72

Published: 2004

Journal Articles

Improved Outcome in Adult T-ALL by Risk Adapted Treatment Strategies.

Nicola Goekbuget, MD, Eckhard Thiel, MD, Joachim Beck, MD, Frank Griesinger, MD, Frank Hartmann, MD, Kathleen Jentsch-Ullrich, MD, Sabine Knipp, MD, Thomas Lipp, MD, Dorle Messerer, Bernd Metzner, MD, Jan Rutjes, MD, Mathias Schmid, MD, Stefan Schwartz, MD, Peter Staib, MD, Matthias Stelljes, MD, Dieter Hoelzer, MD

Blood (2004) 104 (11): 682.

https://doi.org/10.1182/blood.V104.11.682.682

Published: 2004

Journal Articles

Phase 2 Trial of the Histone Deacetylase Inhibitor Valproic Acid as a Monotherapy or in Combination with All-Trans Retinoic Acid in 24 Patients with Acute Myeloid Leukemia.

Andrea Kuendgen, MD, Corinna Strupp, MD, Barbara Hildebrandt, PhD, Sabine Knipp, MD, Baerbel Junge, Rainer Haas, MD, Ulrich Germing, MD, Norbert Gattermann, MD

Blood (2004) 104 (11): 1808.

https://doi.org/10.1182/blood.V104.11.1808.1808

Published: 2004

NARROW

Dependency of Survival on Additional Karyotype Anomalies and Bone Marrow Blast Count in Patients Suffering from Myelodysplastic Syndromes with 5q Deletion.

Defibrotide Effectively Prevents Veno-Occlusive Disease of the Liver (VOD) after Allogeneic Stem Cell Transplantation. An Extended Study.

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.

Induction of Complete Remission with 5-Azacytidine in a Patient with Acute Myeloid Leukemia Refractory to Intensive Chemotherapy.

Exisulind Selectively Induces Apoptosis Via C-Jun Kinase Activation in MDS and sAML/MDS.

A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.

Valproic Acid (VPA) Achieves High Response Rates in Patients with Low-Risk Myelodysplastic Syndromes.

Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes

Intensive Chemotherapy Is Not Recommended for Patients with AML or High-Risk MDS Aged over 60 Years with Complex Karyotype Anomalies.

Improved Outcome in Adult T-ALL by Risk Adapted Treatment Strategies.

Phase 2 Trial of the Histone Deacetylase Inhibitor Valproic Acid as a Monotherapy or in Combination with All-Trans Retinoic Acid in 24 Patients with Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only